Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters

Executive Summary

FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review

You may also be interested in...



FDA Risk “Concept Papers” Expected In March; April Workshop Set

FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization

FDA Risk “Concept Papers” Expected In March; April Workshop Set

FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization

Rx Risk Management Guidances: FDA To Seek Input Through Public Meetings

FDA will hold a series of public meetings on risk assessment, risk management and pharmacovigilance over the next 12 months in preparation for drafting guidances on those topics

Related Content

UsernamePublicRestriction

Register

PS040618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel